论文部分内容阅读
目的 探讨网织红细胞血红蛋白含量 (CHr)在应用促红细胞生成素的终末期肾病 (ESRD)贫血患者补铁治疗中的指导意义。方法 对确诊ESRD的透析患者常规使用促红细胞生成素治疗贫血 ,分别以CHr和铁蛋白及转铁蛋白饱和度 (TSAT)作为铁指标指导补铁 ,比较两组的疗效。结果 CHr组与铁蛋白组疗效无显著性差异 ,但前者使用的铁剂剂量小于后者 (5 86 .14± 2 9.5 4比 5 2 8.99± 39.6 7,P <0 .0 5 )。结论 以CHr作为铁指标指导ESRD透析患者的补铁治疗具有安全、稳定、简便的优点。
Objective To investigate the significance of reticulocyte hemoglobin (CHr) in patients receiving iron supplementation with erythropoietin in patients with end-stage renal disease (ESRD). Methods Dialysis patients diagnosed with ESRD were routinely treated with erythropoietin to treat anemia. The iron contents of CHr, ferritin and transferrin (TSAT) were used as iron markers to guide the iron supplementation. The curative effect was compared between the two groups. Results There was no significant difference between the CHr group and the ferritin group, but the iron dose was lower in the former group than in the latter group (586.14 ± 29.54 vs 528.99 ± 39.67, P <0.05). Conclusion It is safe, stable and simple to use iron as a guide for iron supplementation in ESRD dialysis patients.